Chronic obstructive pulmonary disease (COPD) is a manifestation of structural violence, the process through which societies ...
Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...
COPD-asthma-devices-market2025 PORTLAND, DE, UNITED STATES, January 29, 2025 /EINPresswire / -- Day-to-day exposure to environmental pollutio ...
Eleven drugs are poised to reach blockbuster status, dramatically improving patient outcomes on a global scale.
People with COPD experience more falls and related injuries requiring medical care when using common fall-risk increasing ...
Annual Meeting, researchers presented risk-adjusted findings that shed new light on treatments for severe emphysema.
Medicare beneficiaries may pay less for 15 additional prescription drugs as early as 2027 as part of the next round of federal regulators' price negotiations with pharmaceutical manufacturers.
If these trials confirm the findings, benralizumab could become the first new therapy approved for eosinophilic exacerbations ...
Insights from a study on GLP-1 receptor agonists reveal benefits for cardiometabolic health, with notable risks for ...
The Biden administration on Friday released its next round of prescription drugs selected for Medicare price negotiations, which includes Ozempic.
The newly selected medications are among the costliest for Medicare’s prescription drug program — accounting for about $41 billion in total Medicare Part D spending — and are used by about ...
UK pharma major AstraZeneca’s (LSE: AZN) Fasenra (benralizumab), with its highly anticipated Phase III data to be showcased at the 2025 JP Morgan Healthcare Conference, is set to transform the chronic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback